Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325463 | 1.00 | LOXL2 (0.58) | LOXL2IDO1HRH3AHRHRH4 | |
| SCHEMBL28876221 | 0.98 | LOXL2 (0.56) | LOXL2IDO1HRH3AHRHRH4 | |
| SCHEMBL28876206 | 0.98 | LOXL2 (0.56) | LOXL2IDO1HRH3AHRHRH4 | |
| Ammonia Solution, Strong SCHEMBL28873731 | 0.98 | LOXL2 (0.56) | LOXL2IDO1HRH3AHRHRH4 | |
| Bromide SCHEMBL27641073 | 0.98 | LOXL2 (0.56) | LOXL2IDO1HRH3AHRHRH4 | |
| SCHEMBL28346906 | 0.86 | LOXL2 (0.45) | LOXL2IDO1HRH3AHRHRH4 | |
| SCHEMBL5642064 | 0.82 | LOXL2 (0.60) | LOXL2IDO1HRH3AHRHRH4 | |
| SCHEMBL2592547 | 0.82 | LOXL2 (0.60) | LOXL2IDO1HRH3AHRHRH4 | |
| SCHEMBL6254747 | 0.81 | LOXL2 (0.55) | LOXL2IDO1HRH3AHRHRH4 | |
| SCHEMBL6156791 | 0.81 | LOXL2 (0.55) | LOXL2IDO1HRH3AHRHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121850928-A | 2-Allylindole substituted gem-difluoro olefin compound and preparation method and application thereof | 南京林业大学 | 2026-04-14 | — | — | CN | disclosed |
| CN-121850928-A | 2-Allylindole substituted gem-difluoro olefin compound and preparation method and application thereof | 南京林业大学 | 2026-04-14 | — | — | CN | disclosed |
| CN-119080671-A | Preparation method of 3,3' -bisindolylmethane compound | 南京工业大学 | 2024-12-06 | — | — | CN | disclosed |
| US-20240294538-A1 | Serotonin Receptor Agonists and Methods of Making and Using the Same | KULEON LLC (US) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294538-A1 | Serotonin Receptor Agonists and Methods of Making and Using the Same | HTR1A, HTR7, HTR3A | LOXL2 2837/4885IDO1 577/4885HRH3 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.